Profile data is unavailable for this security.
About the company
Sotac Pharmaceuticals Limited is an India-based pharmaceutical company. The Company's services include contract manufacturing, loan license, formulation and development (F & D) and research and development (R & D). It specializes in manufacturing a range of pharmaceutical products having a therapeutic portfolio including anti-diabetic, anti-psychotic, vitamins, minerals, iron, anti-cold, anti-allergic, dermatological products, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics (IP-Lactams & Non-IP-Lactams), anti-fungal and cephalosporin. It also manufactures nutraceuticals products and food products on contract-manufacturing basis. Its products are supplied across 14 states in India, and it exports its products to over 20 countries worldwide. Its subsidiaries include Sotac Healthcare Private Limited, Sotac Lifesciences Private Limited and Sotac Research Private Limited.
- Revenue in INR (TTM)814.02m
- Net income in INR87.04m
- Incorporated2015
- Employees67.00
- LocationSotac Pharmaceuticals LtdSanand, Plot No. Pf-21Nr. Acme Pharma, Opp. Teva Pharma SanandAHMEDABAD 382110IndiaIND
- Phone+91 9 081993300
- Websitehttps://sotacpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bal Pharma Ltd | 3.09bn | 81.31m | 1.21bn | 986.00 | 15.24 | -- | 6.60 | 0.3912 | 4.99 | 4.99 | 192.78 | -- | -- | -- | -- | 3,138,557.00 | -- | 1.95 | -- | 5.49 | 47.13 | 43.12 | 2.63 | 1.88 | -- | 1.12 | -- | 30.29 | -10.65 | 12.12 | -2.39 | -- | 29.98 | -- |
| Par Drugs and Chemicals Ltd | 1.06bn | 139.06m | 1.22bn | 121.00 | 8.74 | -- | 6.90 | 1.14 | 11.30 | 11.30 | 86.47 | -- | -- | -- | -- | 8,791,298.00 | -- | 13.79 | -- | 16.47 | 58.42 | 43.07 | 13.07 | 14.02 | -- | 137.75 | -- | -- | 5.58 | 12.57 | -7.88 | 22.90 | -4.68 | -- |
| Krebs Biochemicals And Industries Ltd | 230.23m | -228.62m | 1.23bn | 202.00 | -- | -- | -- | 5.36 | -10.60 | -10.60 | 10.68 | -74.60 | -- | -- | -- | 1,139,753.00 | -- | -16.90 | -- | -26.56 | 96.27 | 20.39 | -99.30 | -55.63 | 0.0359 | -2.42 | 3.65 | -- | -14.10 | 5.33 | -36.55 | -- | -17.65 | -- |
| Sotac Pharmaceuticals Ltd | 814.02m | 87.04m | 1.38bn | 67.00 | 15.88 | 2.48 | 9.12 | 1.70 | 7.87 | 7.87 | 73.61 | 50.39 | 0.6818 | 2.86 | 2.67 | 12,149,600.00 | 8.46 | 5.81 | 16.28 | 12.47 | 37.26 | 25.59 | 12.40 | 4.69 | 0.9737 | 2.30 | 0.3854 | -- | -6.59 | 27.66 | 124.25 | 146.89 | 11.66 | -- |
| Alpa Laboratories Limited | 1.14bn | 116.09m | 1.41bn | 453.00 | 12.16 | -- | 10.02 | 1.23 | 5.51 | 5.51 | 53.34 | -- | -- | -- | -- | 2,523,914.00 | -- | 8.59 | -- | 10.61 | 26.16 | 33.75 | 10.15 | 13.40 | -- | -17.25 | -- | -- | 3.41 | 5.52 | 16.25 | 60.11 | 34.92 | -- |
